How to Buy Karyopharm Therapeutics Stock
Karyopharm Therapeutics Inc
Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases.
Karyopharm Therapeutics stock last closed at $0.77, down 3.52% from the previous day, and has decreased 9.75% in one year. It has overperformed other stocks in the Biotechnology industry by 0.06 percentage points. Karyopharm Therapeutics stock is currently +24.47% from its 52-week low of $0.62, and -60.62% from its 52-week high of $1.95.
As of Dec 6, 2024, there are 125.31M KPTI shares outstanding. The market capitalization of KPTI is $96.24M. In the last 24 hours, 1.9M KPTI shares were traded.
How to Buy Karyopharm Therapeutics Stock
Wondering how to invest in Karyopharm Therapeutics stock? Here's how.
- Figure out where to buy Karyopharm Therapeutics stock: You need to pick an online brokerage, but don't worry - we've analyzed dozens of online brokerages and apps to help you choose where to buy Karyopharm Therapeutics stock.
- Sign up for a brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've found.
- Fund your investment account: Pick your payment method and add your information.
- Research Karyopharm Therapeutics stock: The Karyopharm Therapeutics ticker symbol is KPTI. Is Karyopharm Therapeutics stock a good investment? Should you buy shares of KPTI? How do KPTI's underlying business fundamentals look? Do top analysts think Karyopharm Therapeutics is a good buy? Why has KPTI's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if KPTI is a good stock to buy).
- Execute your KPTI trade: Decide if you will purchase KPTI shares at the current market price or use a limit order to buy KPTI shares at a given price.
- Keep an eye on your KPTI position: Create a watchlist to the latest updates on your investment in Karyopharm Therapeutics shares.
Step 1: Figure out where to buy Karyopharm Therapeutics stock
You will need an online brokerage account to access the NASDAQ market and buy KPTI shares.
Our favorite brokerage: eToro
Based on our research, eToro is the best brokerage. Here's why:
- Invest in stocks with 0% commissions: Invest without commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to world financial markets: From Technology to Energy, New York to London — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro offers a community of more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your stock purchase by creating an account with eToro now.
Open eToro AccountStep 2: Sign up for a brokerage account
Now that you've chosen your brokerage, you'll need to fill out some personal information so you are able to buy KPTI stock today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to create your new trading account.
- Submit your application by clicking the "Create Account" button. Get started with eToro today
Step 3: Fund your investment account
Now that you've finished signing up on investing apps, you can securely and quickly fund your account:
Check out the walkthrough below to see the process of transferring funds into your new brokerage account.
Step 4: Research Karyopharm Therapeutics stock
Once you have selected the best place to buy Karyopharm Therapeutics stock, it's crucial to research their stock before you invest, so you truly wrap your head around the risk as well as the upside.
Karyopharm Therapeutics shares quick numbers
Karyopharm Therapeutics Overview
WallStreetZen was designed to help part-time investors perform more accurate fundamental analysis in minutes instead of hours.
You can view all of the due diligence checks on KPTI's stock page.
Is KPTI stock overvalued?
Investors use many financial metrics, analyses, models, and charts to gauge KPTI's true value.
You can do more valuation analysis on KPTI's stock here.
A quick look at KPTI Financials
Passed Health Checks:
- KPTI has $133.87M in cash and short term investments. This is enough to cover its annual cash burn of $120.46M.
- There are more short-term assets than short-term liabilities on the KPTI balance sheet.
- KPTI has cash burn of 120456000. It has sufficient cash and short-term investments to cover this for at least one year.
Failed Health Checks:
- KPTI debt to equity ratio of -2.19 is negative.
- There are more long-term liabilities than short-term assets on the KPTI balance sheet.
- KPTI profit margin has gone up by 0.37 percentage points in the past year, but the company is still unprofitable.
- Total KPTI debt is still negative.
Is KPTI stock a Buy, Hold, or Sell, according to Wall Street analysts?
Out of 4 sell side analysts who give forecasts on KPTI, the consensus analyst rating on Karyopharm Therapeutics is a Strong Buy
It's important to note that analyst forecasts are not stock recommendations, nor are they financial advice.
You can dig deeper into what analysts are projecting on the Karyopharm Therapeutics stock forecast page.
KPTI Technicals
KPTI Earnings
Last year, KPTI revenue was $148.44M. Over the last 5 year, KPTI's revenue has increased by 45.2% per year. This was slower than the Biotechnology industry average of 65.8%.
Find out more about KPTI's earnings and revenue performance here.
Latest Insiders Trades at KPTI
Over the last 12 months, executives and large shareholders at KPTI have sold more shares than they have bought.
Richard A. Paulson, President and CEO of KPTI, was the latest KPTI insider to sell. They sold $2,932.20 worth of KPTI shares on Dec 4, 2024.
Dig into more about who owns KPTI shares here.
Can I rely on KPTI as an income stream?
No, Karyopharm Therapeutics doesn't provide an income stream by paying out dividends.
What do other traders have to say about KPTI?
One of the major reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Execute your KPTI trade
There are two primary order types:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are mostly the best for newer investors. - Limit order: A limit order lets you buy or sell a security at a specific price (or better).
If you want to be certain you're buying or selling at an exact dollar amount limit, use a limit order.
Click the Open Trade button and your broker will place the order.
If you need more info about buying stocks on eToro, click the helpful video below:
Step 6: Keep an eye on your KPTI position
Now that you own some KPTI shares, you'll want to stay up-to-date on your new shares.
Add KPTI to a watchlist to see the latest developments about your KPTI stock.
KPTI Feed
How to Buy Stock in Karyopharm Therapeutics
To summarize, here are the 6 steps you need to take to buy Karyopharm Therapeutics stock right now:
- Figure out where to buy Karyopharm Therapeutics stock
- Sign up for a brokerage account
- Fund your investment account
- Research Karyopharm Therapeutics stock
- Execute your KPTI trade
- Keep an eye on your KPTI position
If you require a brokerage, eToro is our favorite venue.
Get Started with eToro TodayIf you want to get updates on your investment in Karyopharm Therapeutics, add KPTI to your watchlist by clicking the button below.
Trending "How To" Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.